AbbVie Inc. stock at EUR 254.95 ahead of the Xetra open: pharma group rises 0.22 percent

Published on 10/26/2026 at 07:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie develops and sells medicines in immunology, oncology, neuroscience, aesthetics and eye care. At Lang & Schwarz the stock trades pre-market at EUR 254.95 on October 26, 2026, 0.22 percent above the Xetra close of October 23, 2026.

Business model and market context

The company’s revenue model centers on commercializing medicines and healthcare products.
The relevant home-market benchmark is the S&P 500.
AbbVie Inc. stock trades pre-market at EUR 254.95 at 7:38 a.m. CET at Lang & Schwarz on October 26, 2026, 0.22 percent above the Xetra close of October 23, 2026.

Extreme Makroaufnahme irisierender pharmazeutischer Kristallstrukturen unter polarisiertem Mikroskoplicht — AbbVie Inc. US00287Y1091 Makrofotografie irisierender kristalliner Molekülstrukturen unter polarisiertem Mikroskoplicht Biopharma Forschung, Illustration mit AI erstellt.

AbbVie Inc. is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products across immunology, oncology, neuroscience, aesthetics and eye care, according to AbbVie. AbbVie Inc. stock trades pre-market at EUR 254.95 at 7:38 a.m. CET at Lang & Schwarz on October 26, 2026, 0.22 percent above the Xetra close of October 23, 2026 (EUR 254.40).

Ahead of the Xetra open

The pre-market indication is EUR 0.55 above the Xetra close. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of AbbVie stock.

How AbbVie makes its money

The company earns revenue by commercializing medicines and other healthcare products in markets spanning immunology, oncology, neuroscience, aesthetics and eye care, as described by AbbVie.

Market context: Market report S&P 500.

More news and analysis on AbbVie stock